Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
9 hedge funds and large institutions have $1.49M invested in Evoke Pharma in 2015 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 4 closing their positions.
25% less funds holding
Funds holding: 12 → 9 (-3)
38% less capital invested
Capital invested by funds: $2.4M → $1.49M (-$911K)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$224K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$21.4K |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$4.4K |
| 4 |
Renaissance Technologies
New York
|
+$1.26K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FANJ
Financial Architects (New Jersey)
Marlton,
New Jersey
|
-$11K |
| 2 |
Morgan Stanley
New York
|
-$9K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$7K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OM
1
Opaleye Management
Boston,
Massachusetts
| $757K | +$4.4K | +7 | +0.4% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $175K | +$21.4K | +34 | +9% |
|
|
KCM
3
Knoll Capital Management
Miami,
Florida
| $162K | – | – | – |
|
|
4
Millennium Management
New York
| $150K | +$224K | +357 | New |
|
5
California Public Employees Retirement System
Sacramento,
California
| $109K | – | – | – |
|
6
Bank of America
Charlotte,
North Carolina
| $53K | – | – | – |
|
7
Geode Capital Management
Boston,
Massachusetts
| $46K | – | – | – |
|
|
8
Renaissance Technologies
New York
| $38K | +$1.26K | +2 | +2% |
|
|
BIM
9
BlackRock Investment Management
Wilmington,
Delaware
| $1K | – | – | – |
|
|
FANJ
10
Financial Architects (New Jersey)
Marlton,
New Jersey
| – | -$11K | -15 | Closed |
|
|
11
Morgan Stanley
New York
| – | -$9K | -12 | Closed |
|
|
TRCT
12
Tower Research Capital (TRC)
New York
| – | -$7K | -10 | Closed |
|
|
13
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$5K | -7 | Closed |
|
EVOK Hedge Fund Activity: Q3 2015 in Review
9 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q3 2015, worth a combined $1.49M — down 38% from $2.4M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of EVOK and 1 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 3 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $224K. The largest seller was Financial Architects (New Jersey), exiting entirely with an estimated $11K sold.
- 9 institutional investors held Evoke Pharma (EVOK) as of Q3 2015, down from 12 in Q2 2015.
- Funds reported $1.49M of Evoke Pharma stock for Q3 2015, down 38% quarter-over-quarter.
- 1 fund opened new Evoke Pharma positions in Q3 2015 and 4 closed out, a net change of -3 holders.
- The largest Evoke Pharma buyer in Q3 2015 was Millennium Management, an estimated $224K added.
- The largest Evoke Pharma seller in Q3 2015 was Financial Architects (New Jersey), an estimated $11K sold.
Based on aggregated 13F filings for Q3 2015.